Cellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk

Dow Jones

2025/08/15

1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. "We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy," Clammer says. "The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite." Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels "the obligation to lead a company that truly makes the world a safer place every day." Shares rise 9.9% to $15.37. (dean.seal@wsj.com)

(END) Dow Jones Newswires

August 14, 2025 15:31 ET (19:31 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559969733"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559969733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559969733?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 03:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559969733","market":"hk","top_or_hot":-1,"title":"Cellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1531 ET - <a href=\"https://laohu8.com/S/CLBT\">Cellebrite</a>'s newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. (dean.seal@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 15:31 ET (19:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-15 03:31</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1531 ET - <a href=\"https://laohu8.com/S/CLBT\">Cellebrite</a>'s newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. (dean.seal@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 15:31 ET (19:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"應用軟件","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2559969733","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559969733","pubTimestamp":1755199860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","BK4613":"AI应用软件","CLBT":"Cellebrite"},"translate_title":"Cellebrite新任首席执行官在加入最高管理层前一个月战胜了癌症——市场谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLBT":1},"content_text":"1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. (dean.seal@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 15:31 ET (19:31 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}